[ad_1]
ConcertAI has acquired CancerLinQ, an oncology-focused real-world knowledge service, from the American Society of Scientific Oncology (ASCO), for an undisclosed quantity.
Cambridge, Mass.-based ConcertAI is a for-profit firm targeted on oncology real-world knowledge, digital-accelerated scientific trial options, and scientific synthetic intelligence imaging interpretation. The nonprofit ASCO represents almost 50,000 oncology professionals who take care of individuals residing with most cancers.
A narrative in Cancer Letter famous that ConcertAI, via a predecessor agency known as Precision Well being AI, has been working with ASCO for 5 years, curating and licensing the info in CancerLinQ.
Most cancers Letter writer Paul Goldberg requested if the practices that supplied knowledge to ASCO, a nonprofit, would now present the info to a for-profit entity working in a aggressive market.
“I hope so, as a result of I feel that their expertise—the worth they understand from their engagement—goes to change into a greater one,” ASCO’s Chief Govt Officer Clifford Hudis, M.D. responded. “I don’t wish to communicate for no matter ConcertAI might select to do with CancerLinQ, however I feel that the standard of the companies that they obtain ought to quickly enhance.”
Along side the acquisition, ASCO will preserve a multi-year cooperation settlement with CancerLinQ, which was launched by ASCO in 2013. ConcertAI mentioned the brand new enterprise will improve and broaden CancerLinQ’s use of real-world knowledge, analytics, next-generation AI, and different applied sciences to enhance most cancers care and pace scientific analysis.
CancerLinQ represents one of many largest oncology real-world knowledge and high quality of care expertise companies entities on the earth, bringing collectively scientific knowledge from most main EHR techniques. With a community of greater than 100 most cancers facilities and oncology practices, 10 EHR system integrations, and knowledge from almost seven million affected person information, CancerLinQ empowers oncology care groups and researchers with expertise and knowledge improvements to enhance care and speed up most cancers analysis.
CancerLinQ will stay targeted on high quality and advancing the ideas of precision drugs, increasing real-world knowledge for a broader set of analysis functions, and supporting a brand new scientific trials initiative evolving from CancerLinQ’s TriaLinQ ideas. CancerLinQ will work intently with ASCO to prioritize the wants of oncology practices and assist the enlargement of the apply community.
“We consider this settlement will present the assets to meet and amplify CancerLinQ’s impression, whereas permitting ASCO to harness the CancerLinQ platform for high quality enchancment initiatives and CancerLinQ Discovery knowledge for analysis to assist our mission,” mentioned ASCO’s Hudis in a press release. “We anticipate CancerLinQ to be an vital avenue for practices to realize certification underneath ASCO’s just lately launched ASCO Licensed program.”
“CancerLinQ could also be one of the vital oncology networks in existence. We’re happy and privileged to have the ability to advance the unique high quality enchancment objectives and follow-on analysis pursuits of CancerLinQ in collaboration with ASCO, with urgency and alacrity,” mentioned Jeff Elton, Ph.D., CEO of ConcertAI, in a press release. “We’re committing greater than $250 million to the standard options, knowledge options, and novel scientific trial options over the approaching few years to realize the very best high quality care, speed up wanted new biomedical improvements, and guarantee the absolute best outcomes for sufferers.”
ConcertAI will collaborate with ASCO to considerably improve the worth of CancerLinQ for oncology practices and their sufferers by:
• Bolstering SmartLinQ to incorporate new knowledge sources alongside the sturdy scientific knowledge at the moment accessible
• Making scientific trials participation extra accessible and fewer burdensome via ConcertAI’s Digital Entry to Scientific Trial (DACT) platform
• Creating extra sturdy scientific determination assist inside SmartLinQ
• Supporting automated EHR integration, bringing SmartLinQ seamlessly into practices’ workflows
“The scope and scale of what CancerLinQ and ConcertAI can accomplish collectively is unprecedented,” mentioned Eric P. Winer, M.D., chair of the board of ASCO, in a press release. “We’ve efficiently constructed a real-world knowledge platform that delivers actionable insights to the most cancers neighborhood – and now CancerLinQ is poised to maintain and enhance its impression for oncology practices and sufferers for the long run.”
[ad_2]
Source link
